Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is well-positioned for growth in the pharmaco-epigenetics space, bolstered by ongoing collaborations and partnerships that could enhance revenue and adoption of its biomarker technology. The significant validation of the Nu.Q Lung Cancer Test, along with discussions with major diagnostic and pharmaceutical companies, indicates a trajectory toward successful strategic partnerships, which would de-risk the company’s technological investments. Additionally, the successful adoption of its Nu.Q Discover biomarkers in over 1,000 veterinary hospitals in Japan points to strong market interest and potential for increased revenue, particularly with the imminent transition to an automated system.

Bears say

VolitionRX Ltd is attempting to address significant challenges related to high false-positive rates in low-dose computed tomography (LDCT) screenings, which may hinder its ability to gain traction in the diagnostic market despite its innovative Nucleosomics platform. The high rate of unnecessary invasive procedures associated with the company's testing approach could adversely affect its reputation and adoption among healthcare providers, potentially impacting future revenue growth. Additionally, the focus on human diagnostics alongside animal diagnostics may dilute the company’s resources and strategic focus, creating further uncertainties around its financial performance and marketability.

Volitionrx Limited (VNRX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.